RxDoctor Payments Data

Uloma Ibe, MD

Family Medicine · Largo, MDNPI 1649667940

Payments from drug & device makers

$1,615in general payments, 2019–2025

Across 59 payments — averaging $27.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$423
  • Sanofi-aventis U.S. LLC$279
  • Sun Pharmaceutical Industries Inc.$211
  • Lilly USA, LLC$136
  • Exact Sciences$90
  • Mylan Pharmaceuticals Inc.$75
  • plus $401 from 14 others

What the payments were for

  • Food & beverage$1,615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,615 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$64,760
Medicare patients
156
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$25,633
OzempicSemaglutide14$18,878
Atorvastatin Calcium75$670
Losartan Potassium52$497
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide29$452
Ibuprofen27$352
Nifedipine ErNifedipine16$349
Famotidine18$349
Pravastatin Sodium14$335
Chlorthalidone11$296
Cyclobenzaprine Hcl14$295
Meclizine Hcl18$262
Potassium Chloride16$187
Baclofen11$183
Amlodipine Besylate51$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$423$18,87814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Largo

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →